Research programme: anticancer therapeutics - China Pharmaceutical University/ Johnson and Johnson InnovationAlternative Names: Solid tumour therapeutics - China Pharmaceutical University/Johnson and Johnson Innovation
Latest Information Update: 03 Nov 2014
At a glance
- Originator China Pharmaceutical University; Johnson & Johnson Innovation
- Class Immunoconjugates
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 28 Oct 2014 Early research in Solid tumours in China (unspecified route)